Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 29Gastrointestinal 16Gynecologic 6Thoracic 5Tumor-Agnostic 4CNS 4Sarcoma 3Head & Neck 3Genitourinary 2Dermatologic 1

Conditions

Neoplasm Metastasis 4

Interventions

pembrolizumab 24Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 19Paclitaxel 11Standard of Care 10Bevacizumab 10atezolizumab 9Carboplatin 9Nivolumab 8Cisplatin 8Blood Specimen Collection 8Surveys and Questionnaires 7Capecitabine 7Radiosurgery 6Pemetrexed 6Gemcitabine 6Cyclophosphamide 6durvalumab 5Taxes 5Irinotecan 5trastuzumab deruxtecan 4olaparib 4niraparib 4cabozantinib 4X-Rays 4Radiotherapy 4Oxaliplatin 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
trastuzumab deruxtecan × Tumor-Agnostic × 90 days × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04639219 2026-03-23

DPT01

AstraZeneca

Phase 2 Active not recruiting
102 enrolled 18 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡